News

The SISTER trial finds 1:1 peer support significantly improves endometrial cancer treatment completion for Black women, per 2026 SGO Meeting data.

Eliya Shachar, UCLA Health, says toxicity risk is not independently tied to age or demographics, reinforcing consistent monitoring and individualized care for all patients.

FDA accepted the NDA for TLX101-Px, a PET imaging agent for glioma, with a Sept. 11, 2026 decision date, aiming to improve assessment of tumor progression.

Nurses can catch early IO toxicities through routine symptom checks and support long-term care, as effects may persist after treatment ends.

A program promoting systemwide change, staff engagement and safety culture may improve chemotherapy administration and toxicity management globally, expert says.

Gotistobart reduced death risk by 54% and doubled 12-month survival vs chemo in pretreated advanced squamous NSCLC, per PRESERVE-003 results.

High patient loads, limited advocacy roles and unsafe work environments challenge oncology nurses in low- and middle-income countries.

Nuvalent submitted an NDA for neladalkib in TKI-pretreated ALK+ NSCLC, supported by ALKOVE-1 data showing systemic and intracranial activity with tolerability.

Zongertinib elicited responses in patients with advanced HER2-mutant NSCLC, showing intracranial efficacy in those with active brain metastases, per phase 1b Beamion LUNG-1 data.

Thomas W. Flaig, MD, discusses the 2026 NCCN Guidelines updates for bladder cancer, highlighting the role of enfortumab vedotin, pembrolizumab, and the shift toward neoadjuvant ADC therapy.

Learn about the rising cancer burden, the importance of patient navigation, and strategies to close the equity gap in low-resource settings.

New NCCN Guidelines for colorectal cancer emphasize structured exercise and molecular profiling to reduce recurrence.

Sandy Srinivas, MD, of Stanford Cancer Center, discusses the critical role of patient selection, chemo-fitness, and managing comorbidities when selecting ARPI doublets for older patients with prostate cancer.

The FDA has granted full approval to brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma based on ZUMA-2 data.

Explore how oncology nurses can address the rising incidence of early-onset cancer through tailored support for fertility, financial toxicity, and survivorship.

The CHRONOS study highlights a 29% 12-month survival rate for third-line GI-aGvHD, underscoring an urgent need for standardized therapies after ruxolitinib failure.

Why is "chemotherapy" being phased out? MiKaela M. Olsen, DNP, APRN-CNS, AOCNS®, FAAN, joins Onc Nurse on Call to break down the new ASCO-ONS safety standards for oncology nurses.

The FDA has granted Fast Track designation to the FRα-targeting ADC ZW191 as a potential treatment for patients with for platinum-resistant ovarian cancer.

Anurag K. Agrawal, MD, of the American Cancer Society, discusses global oncology nursing challenges, including high patient ratios, hierarchy, and chemo safety.

Adagrasib shows efficacy in elderly patients with KRAS G12C-mutant NSCLC and an ECOG PS of 0-1, while those with a PS of 2 see limited survival benefit but QOL improvements.

Hardik Thakkar, MSPAS, PA-C, discusses the ways in which NPs and PAs can benefit from each other’s specialized training.

Calderasib, a potent KRAS G12C inhibitor, demonstrated improved outcomes in patients with metastatic NSCLC, especially when combined with pembrolizumab.

Explore phase 1 data for setidegrasib, a novel KRAS G12D-targeted protein degrader showing antitumor activity and manageable infusion-related reactions in patients with advanced NSCLC.

Natalia Neparidze, MD, discusses subcutaneous daratumumab safety, MRD as a clinical endpoint, and emerging therapies for multiple myeloma management.

Research presented at the APOS Conference demonstrated negative beliefs in parents and caregivers of pediatric patients with cancer.

The FDA approved the combination of relacorilant and nab-paclitaxel in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

A physician, physician assistant, and nurse practitioner share perspectives on integrative medicine in oncology.

Amber Altidor, NP, shares how oncology nurses can use teach-back methods and learning style assessments to improve patient education on medication toxicities.